Using genetically modified pigs to understand immune responses to influenza
Genetically modified pigs to model NKT cell immunity to influenza virus infection
This study is looking at how a special kind of immune cell called NKT cells helps protect against the flu by using genetically modified pigs that don’t have these cells, which could lead to better ways to prevent and treat flu in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11056720 on NIH RePORTER |
What this research studies
This research investigates the role of a specific type of immune cell, known as NKT cells, in protecting against influenza virus infections. By creating genetically modified pigs that lack these cells, researchers aim to understand how NKT cells influence the body's immune response to the virus. The study will utilize these pigs to explore how the absence of NKT cells affects virus shedding and overall immunity, providing insights that could be applicable to human health. The findings may help in developing better strategies for preventing and treating influenza.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of severe influenza infections or those at high risk for complications from the virus.
Not a fit: Patients who do not have a history of influenza infections or those with unrelated respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccines and therapies for influenza, enhancing patient protection against the virus.
How similar studies have performed: Previous research has shown promise in using animal models to study immune responses, indicating that this approach could yield valuable insights.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Driver, John — University of Missouri-Columbia
- Study coordinator: Driver, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.